Unknown PHASE2 INTERVENTIONAL 1-arm NCT04858997

Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients

An Open-label, Prospective Study of Tumor Response Time of Palbociclib in Combination With AI in Real-world First-line Treatment of Postmenopausal Chinese Patients With ER (+) HER2 (-) Metastatic Breast Cancer

Sponsor: Pfizer

Conditions Breast Neoplasms

Interventions AI Palbociclib

Updated 5 times since 2021 Last updated: Jul 13, 2021 Started: Apr 22, 2021 Primary completion: Dec 31, 2022 Completion: Jun 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04858997, this PHASE2 trial focuses on Breast Neoplasms and remains ongoing. Sponsored by Pfizer, it has been updated 5 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Aug 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Sep 2021 — Aug 2023 [monthly]

Recruiting PHASE2
May 2021 — Sep 2021 [monthly]

Recruiting PHASE2

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer
Zhejiang Cancer Hospital

Data source: Zhejiang Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China